Food-Derived Peptides That Lower Blood Pressure: How They Work and Where They Come From
Food-derived peptides that block the blood-pressure-raising enzyme ACE show promise as natural alternatives to pharmaceutical ACE inhibitors, though bioavailability and clinical evidence gaps remain.
Quick Facts
What This Study Found
Food-derived ACE-inhibitory peptides — obtained through natural extraction, enzymatic hydrolysis, or fermentation of foods — can block the angiotensin-converting enzyme (ACE), a key driver of high blood pressure. This review maps the landscape of these peptides: their food sources, how they're produced, their structural characteristics, and their antihypertensive activity in both lab and animal studies.
The production method significantly shapes which peptides are generated and how well they work — peptide chain length, amino acid composition, and sequence all determine ACE-inhibitory potency. Bioavailability remains a key challenge, as peptides must survive digestion to reach the bloodstream.
Key Numbers
Multiple food sources characterized · Production methods: extraction, enzymatic hydrolysis, fermentation · Structural determinants: chain length, amino acid composition, sequence · In vitro and in vivo activity data reviewed
How They Did This
Systematic narrative review of published literature on food-derived ACE-inhibitory peptides, covering their sources, production methods, structural characteristics, mechanisms of action, in vitro and in vivo activity, and bioavailability.
Why This Research Matters
Hypertension affects roughly 1.3 billion people worldwide and is the leading modifiable risk factor for heart disease and stroke. Standard ACE inhibitor drugs (like lisinopril) are effective but come with side effects including persistent cough and angioedema. Food-derived ACE-inhibitory peptides could offer a natural, lower-side-effect approach to blood pressure management — either as supplements or functional foods. Understanding their mechanisms and bioavailability is essential for translating them from lab curiosity to practical health intervention.
The Bigger Picture
The functional food and nutraceutical market is booming, and blood-pressure-lowering peptides are among the most commercially developed bioactive peptides. Products like Lactobacillus-fermented milk drinks containing ACE-inhibitory tripeptides (VPP and IPP) have been marketed in Japan and Europe. This review provides the scientific foundation for understanding which peptides work, why, and what challenges remain in making them effective real-world interventions.
What This Study Doesn't Tell Us
This is a review, not a primary study. Most evidence for food-derived ACE-inhibitory peptides comes from in vitro assays and animal studies — human clinical data is relatively limited. Lab-measured ACE inhibition doesn't always translate to real blood pressure reduction in living systems because of bioavailability challenges. The review doesn't systematically grade evidence quality across studies.
Questions This Raises
- ?Which food-derived ACE-inhibitory peptides have the strongest human clinical evidence for blood pressure reduction?
- ?Can encapsulation or other delivery technologies solve the bioavailability problem for oral peptide supplements?
- ?How do food-derived ACE-inhibitory peptides compare in potency and side effect profile to pharmaceutical ACE inhibitors?
Trust & Context
- Key Stat:
- Natural ACE blockers Peptides from foods like milk, fish, and soybeans can inhibit the same enzyme targeted by pharmaceutical blood pressure drugs
- Evidence Grade:
- This is a review article synthesizing primarily in vitro and animal data. While the ACE-inhibitory mechanism is well-established, human clinical evidence for most specific food-derived peptides is limited.
- Study Age:
- Published in 2025 in Life (Basel). This is a current review capturing the latest advances in a field that has been growing for over two decades.
- Original Title:
- Research Progress on the Mechanism of Action of Food-Derived ACE-Inhibitory Peptides.
- Published In:
- Life (Basel, Switzerland), 15(8) (2025)
- Authors:
- Li, Ting(3), Du, Wanjia, Huang, Huiyan, Wan, Luzhang, Shang, Chenglong, Mao, Xue, Kong, Xianghui
- Database ID:
- RPEP-12102
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can eating certain foods actually lower blood pressure through peptides?
Potentially. Peptides from milk, fish, soybeans, and fermented foods have been shown to block ACE in laboratory studies and lower blood pressure in some animal and human studies. However, the effect is generally modest compared to pharmaceutical drugs, and the peptides must survive digestion to work — which is a significant challenge. Some fermented milk products with these peptides are already sold commercially.
How do food peptides compare to blood pressure medications?
Food-derived ACE-inhibitory peptides are much weaker than pharmaceutical ACE inhibitors like lisinopril. Their advantage is a better safety profile with fewer side effects. They're best viewed as a complementary approach — potentially helpful for borderline blood pressure or alongside medication — rather than a replacement for prescribed drugs. Always consult your doctor before relying on supplements for blood pressure management.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-12102APA
Li, Ting; Du, Wanjia; Huang, Huiyan; Wan, Luzhang; Shang, Chenglong; Mao, Xue; Kong, Xianghui. (2025). Research Progress on the Mechanism of Action of Food-Derived ACE-Inhibitory Peptides.. Life (Basel, Switzerland), 15(8). https://doi.org/10.3390/life15081219
MLA
Li, Ting, et al. "Research Progress on the Mechanism of Action of Food-Derived ACE-Inhibitory Peptides.." Life (Basel, 2025. https://doi.org/10.3390/life15081219
RethinkPeptides
RethinkPeptides Research Database. "Research Progress on the Mechanism of Action of Food-Derived..." RPEP-12102. Retrieved from https://rethinkpeptides.com/research/li-2025-research-progress-on-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.